Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Smriti Gurung, Colin Crean, David Lloyd Halladay, Judith L. Anderson, Rafat Abonour, Brian A. Walker, Kelvin P. Lee, John Mitchell Chirgwin, Attaya Suvannasankha

Blood (2024) 144 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2024-211787

Published: 2024

Journal Articles

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Ehsan Malek, Kimberly Crasti, Grant Schofield, Shernan G. Holtan, Megan M Herr, Marco Davila, You-Wen Qian, Brian Betts, Mackenzie Lieberman, Jason Tong, Colin Chavel, Kelvin P. Lee, Scott Olejniczak

Blood (2024) 144 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2024-198255

Published: 2024

Journal Articles

Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Christopher Rolf Schorr, Daniela Nicoleta Petrusca, Louise Carlson, Joyce Hardwick, Julia Grace Reinke, Kelvin P. Lee

Blood (2024) 144 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2024-193753

Published: 2024

Journal Articles

Role of Tryptophan Metabolizing Enzymes in Multiple Myeloma Survival

Julia Grace Reinke, Peng Peng, Daniela Nicoleta Petrusca, Kanita Chaudhry, Louise Carlson, Christopher Rolf Schorr, Kelvin P. Lee

Blood (2024) 144 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2024-211044

Published: 2024

Journal Articles

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Veronica Canarte, Tyler Moser-Katz, Catherine Gavile, Benjamin G. Barwick, Kelvin P. Lee, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2023-190453

Published: 2023

Journal Articles

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Setarah Mohammad Nader, S. Tyler Jines, Christopher Collier, Teresa Zimmers, Rafat Abonour, Sherif Farag, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2023-182754

Published: 2023

Journal Articles

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Enze Liu, Nathan Becker, Parvathi Sudha, Aneta Mikulasova, Mohammad Abu Zaid, Attaya Suvannasankha, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 641.

https://doi.org/10.1182/blood-2023-186262

Published: 2023

Journal Articles

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Phillip Pham, Parvathi Sudha, Lin Wang, Wen Niu, Cameron Morgan, Cameron Ligocki, Ramzi Al-Azzawi, Reynold Ly, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2023-180116

Published: 2023

Journal Articles

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Adam Stepanovic, Rafat Abonour, Mohammad Abu Zaid, Sherif Farag, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2023-183085

Published: 2023

Journal Articles

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Othman Salim Akhtar, Jens Hillengass, Brea Lipe, Sheila A. Figel, Robert A. Fenstermaker, Michael J. Ciesielski, Kelvin P. Lee

Blood (2022) 140 (Supplement 1): 10170–10171.

https://doi.org/10.1182/blood-2022-163597

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C

Adam Utley, PhD, Kelvin P. Lee, MD, Mark Hicar, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-143064

Published: 2020

Journal Articles

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142622

Published: 2020

Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 957.

https://doi.org/10.1182/blood-2018-99-113548

Published: 2018

Journal Articles

CD28 Induces Metabolic Fitness in Multiple Myeloma for ROS-Dependent Survival

Adam Utley, BS, BA, Peng Peng, Wensheng Liu, Daniella Ventrone, Kelvin P. Lee, MD

Blood (2018) 132 (Supplement 1): 3220.

https://doi.org/10.1182/blood-2018-99-119496

Published: 2018

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

CD28 Induces Mitochondrial Respiration through Irf4 for Long Lived Plasma Cells Survival

Adam T. Utley, BS, BA, Louise Carlson, BS, Kelvin P. Lee, MD

Blood (2016) 128 (22): 128.

https://doi.org/10.1182/blood.V128.22.128.128

Published: 2016

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

CD28 Induces Mitochondrial Respiration through Slp-76 in Long-Lived Plasma Cells for Reactive Oxygen Species-Dependent Survival

Adam T. Utley, BS, BA, Daniela Ventro, PhD, Megan Murray, MD PhD, Amin Mahpour, BS, MS, Kelvin P. Lee, MD

Blood (2015) 126 (23): 288.

https://doi.org/10.1182/blood.V126.23.288.288

Published: 2015

Journal Articles

In Situ CD28-CD86 Interactions on Myeloma - Targeting the Achilles Heel

Jayakumar R. Nair, PhDMSc,BSc, Louise Carlson, BS, Kelvin P. Lee, MD

Blood (2015) 126 (23): 4184.

https://doi.org/10.1182/blood.V126.23.4184.4184

Published: 2015

NARROW

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Role of Tryptophan Metabolizing Enzymes in Multiple Myeloma Survival

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

CD28 Induces Metabolic Fitness in Multiple Myeloma for ROS-Dependent Survival

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

CD28 Induces Mitochondrial Respiration through Irf4 for Long Lived Plasma Cells Survival

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

CD28 Induces Mitochondrial Respiration through Slp-76 in Long-Lived Plasma Cells for Reactive Oxygen Species-Dependent Survival

In Situ CD28-CD86 Interactions on Myeloma - Targeting the Achilles Heel

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only